TrialNature medicine2025

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Georgina V Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.